Breaking Barriers: Delivering Therapeutics to the Brain in Alzheimer's Disease.
作者信息
De Strooper Bart, Scheltens Philip, Salloway Stephen
机构信息
Center for Brain and Disease research at VIB@KULeuven, University of Leuven, Belgium and Laboratory of the cellular phase of Alzheimer's Disease at UKDRI@University College London, UCL, UK.
EQT Life Sciences, Amsterdam, The Netherlands.
出版信息
J Prev Alzheimers Dis. 2025 Aug;12(7):100229. doi: 10.1016/j.tjpad.2025.100229. Epub 2025 Jun 13.
Abstract
摘要
相似文献
1
Breaking Barriers: Delivering Therapeutics to the Brain in Alzheimer's Disease.突破障碍：在阿尔茨海默病中将治疗药物送达大脑
J Prev Alzheimers Dis. 2025 Aug;12(7):100229. doi: 10.1016/j.tjpad.2025.100229. Epub 2025 Jun 13.
2
A microglia clonal inflammatory disorder in Alzheimer's disease.阿尔茨海默病中的一种小胶质细胞克隆性炎症性疾病。
Elife. 2025 Mar 14;13:RP96519. doi: 10.7554/eLife.96519.
3
The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.亚洲阿尔茨海默病所致轻度认知障碍的患者诊疗路径：当前实践、障碍及优化的专家建议
J Prev Alzheimers Dis. 2025 Aug;12(7):100215. doi: 10.1016/j.tjpad.2025.100215. Epub 2025 Jun 6.
4
Plant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer's disease.基于植物的类黄酮及其纳米颗粒：对抗阿尔茨海默病的最新武器。
Drug Deliv Transl Res. 2025 Jun 30. doi: 10.1007/s13346-025-01906-9.
5
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2015 Apr 10(4):CD001191. doi: 10.1002/14651858.CD001191.pub3.
6
Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer's disease.正常衰老和阿尔茨海默病中脑内皮细胞转录组异质性的见解
Neural Regen Res. 2026 Feb 1;21(2):569-576. doi: 10.4103/NRR.NRR-D-24-00695. Epub 2024 Dec 16.
7
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.
8
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.脑源性 tau：阿尔茨海默病型神经退行性变的新型基于血液的生物标志物。
Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407.
9
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.抗淀粉样蛋白β单克隆抗体治疗阿尔茨海默病的疗效和安全性的系统评价。
Expert Opin Biol Ther. 2024 Nov;24(11):1261-1269. doi: 10.1080/14712598.2024.2416947. Epub 2024 Nov 12.
10
Short-lived Niemann-Pick type C mice with accelerated brain aging as a novel model for Alzheimer's disease research.作为阿尔茨海默病研究的新型模型的具有加速脑老化的短寿命尼曼-皮克C型小鼠。
Neural Regen Res. 2025 Apr 29. doi: 10.4103/NRR.NRR-D-24-01190.
本文引用的文献
1
Drug delivery strategies to cross the blood-brain barrier in Alzheimer's disease: a comprehensive review on three promising strategies.阿尔茨海默病中跨越血脑屏障的药物递送策略：对三种有前景策略的全面综述
J Prev Alzheimers Dis. 2025 Aug;12(7):100204. doi: 10.1016/j.tjpad.2025.100204. Epub 2025 May 19.
2
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.针对转铁蛋白受体将反义寡核苷酸转运穿过哺乳动物血脑屏障。
Sci Transl Med. 2024 Aug 14;16(760):eadi2245. doi: 10.1126/scitranslmed.adi2245.
3
Identification and in vivo characterization of a brain-penetrating nanobody.鉴定和体内鉴定一种可穿透血脑屏障的纳米抗体。
Fluids Barriers CNS. 2020 Oct 14;17(1):62. doi: 10.1186/s12987-020-00226-z.
4
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.通过降低治疗性抗体对转胞吞作用靶点的亲和力来提高其脑内摄取。
Sci Transl Med. 2011 May 25;3(84):84ra44. doi: 10.1126/scitranslmed.3002230.
5
The blood-brain barrier: bottleneck in brain drug development.血脑屏障：脑药物研发的瓶颈
NeuroRx. 2005 Jan;2(1):3-14. doi: 10.1602/neurorx.2.1.3.
6
Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits.兔血脑屏障的无创磁共振成像引导下局灶性开放
Radiology. 2001 Sep;220(3):640-6. doi: 10.1148/radiol.2202001804.
7
The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.粒径和电荷对脂质体及脂质体包封药物清除率的影响。
Biochem Biophys Res Commun. 1975 Apr 7;63(3):651-8. doi: 10.1016/s0006-291x(75)80433-5.
Zotero 插件